The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression

Thyroid

Volumn 22, Issue 4, 2012, Pages 377-382

  Grabellus, Florian ^a   Worm, Karl ^a   Schmid, Kurt Werner ^a   Sheu, Sien Yi ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B RAF KINASE; FORMALDEHYDE; GENOMIC DNA; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; PARAFFIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; WILD TYPE;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CELL PROLIFERATION; DNA, NEOPLASM; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84859363753     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0401     Document Type: Article

References (38)

1. Vander Heiden MG, Cantley LC, Thompson CB 2009 Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
2. Macheda ML, Rogers S, Best JD 2005 Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662. (Pubitemid 40175840)
3. Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY 2012 Glucose transporter 1 (GLUT1) expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly-differentiated thyroid carcinoma. Clin Nucl Med 37:121-127.
4. Ganapathy V, Thangaraju M, Prasad PD 2009 Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29-40.
5. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
6. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222. (Pubitemid 43740191)
7. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS 2006 Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244:799-804. (Pubitemid 44629955)
8. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090. (Pubitemid 350074715)
9. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404. (Pubitemid 37452745)
10. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379. (Pubitemid 41759286)
11. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93.
12. Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M 2011 Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: A clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab 96:E19-E30.
13. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Jr., Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N 2009 Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325:1555-1559.
14. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840-2843. (Pubitemid 47037399)
15. DeLellis RA, Lloyd RV, Heitz U, Eng C 2004 World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon.
16. Remmele W, Stegner HE 1987 [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138-140.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
18. Miles KA, Williams RE 2008 Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 8:81-86. (Pubitemid 351517291)
19. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W 1996 Fluorine-18-FDG and iodine- 131-iodide uptake in thyroid cancer. J Nucl Med 37:1468-1472. (Pubitemid 26321624)
20. Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE 1997 GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7:363-367.
21. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y 2005 Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499-1504.
22. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR 2010 The XbaI G T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med 51:1191-1197.
23. Reis H, Tschirdewahn S, Szarvas T, Rü bben H, Schmid KW, Grabellus F 2011 Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncol Lett 2:1149-1153.
24. Scholzen T, Gerdes J 2000 The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311-322. (Pubitemid 30054364)
25. van Diest PJ, van Der Wall E, Baak JP 2004 Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 57:675-681. (Pubitemid 38901478)
26. Elston CW, Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology 19:403-410.
27. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW 2002 Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465. (Pubitemid 34747864)
28. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J 1997 Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350-362. (Pubitemid 27020593)
29. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595.
30. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
31. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931.
32. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Jr., Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
33. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE, Jr., Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330.
34. Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM 2005 An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65:9633-9636. (Pubitemid 41541437)
35. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ 2009 Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCRABL- positive cells. Clin Cancer Res 15:3442-3450.
36. Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK 2010 Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70:2476-2484.
37. Ulanovskaya OA, Cui J, Kron SJ, Kozmin SA 2011 A pairwise chemical genetic screen identifies new inhibitors of glucose transport. Chem Biol 18:222-230.
38. Amann T, Hellerbrand C 2009 GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 13:1411-1427.